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Summary At present there are strong indications of a shared vulnerability factor for schizo-
phrenia (SZ), diabetes and the metabolic syndrome (metS). In this study we focus on an aberrantly
activated monocyte/macrophage system as the shared factor.
We measured in SZ patients (n = 144), the serum levels of monocyte/macrophage cytokines/
chemokines/adipokines CCL2, CCL4, IL-1b, TNF-a, IL-6, PTX3, leptin, adiponectin, PAI-1, OPG
and ICAM-1 and compared these levels to healthy controls (HC) (n = 138). Using multivariate
analysis, we studied the effect of the presence of the disease SZ, the components of the metS
including BMI, the levels of lipids (HDL cholesterol and triglycerides (TG)), diabetes (hyperglyce-
mia) and the use of antipsychotic medication, on the serum levels of these immune compounds.
We found all measured immune compounds with the exception of PAI-1 and OPG to be elevated
in the SZ patient population. Multivariate analysis showed that elevations were linked to gender
(ICAM-1, leptin, TNF-a and adiponectin), an increased BMI (leptin, adiponectin), hyperglycemia/
diabetes (CCL4, and OPG), reduced HDL-cholesterol or increased levels of TG (adiponectin and
PTX3) or the metS (CCL2, leptin and adiponectin). IL-1b and IL-6 were the only immune
compounds raised in the serum of patients not affected by any of the included factors.
Although many of the immune compounds were found linked to (components of) the metS, the
most dominant linkage was found with the disease schizophrenia, confirming earlier reports on
increased monocyte/macrophage activation as a key component for understanding the patho-
genesis of schizophrenia.
# 2012 Elsevier Ltd. 
* Corresponding author at: Dept. of Immunology, Erasmus MC, Dr. Molenwaterplein 50, 3015CE Rotterdam, The Netherlands.
Tel.: +31 0107044091; fax: +31 10704 4731.
E-mail address: w.beumer@erasmusmc.nl (W. Beumer).
1 These authors contributed equally to this work.
Available online at www.sciencedirect.com
j our na l h omepa g e: www.e l se v ie r.c om/l oca te/ psyne ue n
0306-4530  # 2012 Elsevier Ltd. 
Open access under the Elsevier OA license.
Open access under the Elsevier OA license.
http://dx.doi.org/10.1016/j.psyneuen.2012.04.001
1902 W. Beumer et al.1. Introduction
Increased prevalence of both components and the metS
itself has been a systematic finding in metabolic research
in SZ (De Hert et al., 2006). It is well known that 1 year of
antipsychotic drug treatment in the first episode of schizo-
phrenia induces clinical relevant weight gain and rise of
fasting plasma glucose levels (Kahn et al., 2008). In a cross-
sectional study of 200 Caucasian patients with SZ or schi-
zoaffective disorder (mean age 41 years) the prevalence of
hyperglycemia was 7% and that of type 2 DM 14.5%, being
significantly increased compared to the general population
(Cohen et al., 2006b). However, the development of dia-
betes was unrelated to duration of antipsychotic treatment
or to a specific antipsychotic drug (Cohen et al., 2006a),
suggesting that disease-related instead of treatment-
related effects determined the higher risk for diabetes.
Studies in drug-naı¨ve SZ patients suggests that diabetes
and the metS are linked to the to the disease state schizo-
phrenia itself (Ryan et al., 2003). This direct linkage was
already suggested in 1879 by Sir Maudsley in his paper
‘‘Diabetes and Insanity’’ far before the era of antipsychotic
medication, where he noted that diabetes was more pre-
valent in psychotic patients and their family members
(Maudsley, 1879). A more recent paper found increased
diabetes prevalence and increased IL-6 blood concentrations
in drug-naı¨ve recent onset SZ patients, irrespective of BMI,
gender, age and other confounding factors (Fernandez-Egea
et al., 2009).
Presently there are strong indications that several vul-
nerability factors for schizophrenia, diabetes and the metS
are shared (Mitchell and Malone, 2006; De Hert et al., 2011)
and possibly interlinked. We focus in this report on the
contribution of an aberrantly activated monocyte/macro-
phage system.
Evidence is accumulating that an aberrantly activated
monocyte/macrophage system found in SZ patients is a
key to the understanding of the disease. We previously
reported on monocytosis and an up regulated inflammatory
gene expression profile in circulating monocytes of SZ
patients involving genes such as
IL-1b, TNF-a, IL-6, PTX3, CCL2 and CCL4 (Drexhage et al.,
2010b). Also increases in the serum concentrations of these
cytokines and chemokines have been reported in SZ patients
(data reviewed in Drexhage et al., 2010a). It is thought that
these excessively produced immune compounds destabilize
the brain in such a way that other genetic and environmental
influences are capable of precipitating the signs and symp-
toms of SZ (Smith, 1992; Smith and Maes, 1995). Indeed,
receptors for inflammatory cytokines are expressed in var-
ious brain nuclei (Silberstein et al., 2009) and via their
triggering, deregulations of important neurotransmitter
and neuro-developmental systems are introduced, facilitat-
ing the development of psychiatric signs and symptoms.
Moreover, infusion with pro-inflammatory cytokines (such
as IFN-a and TNF-a) is capable of inducing psychiatric symp-
toms (Keefe, 2007; Khairova et al., 2009). Anti-inflammatory
therapies, such as anti-TNF (Soczynska et al., 2009), COX-2
inhibitors (Muller et al., 2002, 2010; Akhondzadeh et al.,
2007), aspirin (Laan et al., 2010) and strong macrophage-
dampening anti-oxidants, such as n-acetyl cysteine (NAC)
(Dodd et al., 2008; Dean et al., 2011), are capable ofalleviating symptoms of depression and SZ. Furthermore,
increased levels of the osteoclastogenesis factor OPG have
been described in SZ patients (Hope et al., 2010). OPG is a
member of the tumor necrosis factor receptor family and
known to act as a competitive decoy receptor for RANKL
preventing the genesis of the macrophages of the bone, the
osteoclasts. Interestingly SZ patients also have a higher
frequency of osteoporosis (Hummer et al., 2005; Meyer
and Lehman, 2006)
An aberrantly activated monocyte/macrophage system is
also a key player in T2D and the metS. In T2D monocytes/
macrophages are involved by excessively secreting inflam-
matory cytokines (such as CCL2 and TNF-a), which are cap-
able of inducing insulin-resistance in muscle and liver cells
(Kamei et al., 2006; Drexhage et al., 2008).
In patients with obesity, macrophages in the white adipose
tissue are in a chronic inflamed state and produce an array of
(pro-inflammatory) cytokines including ICAM-1, CCL2, CCL4,
IL-1b, TNF-a, IL-6, leptin, adiponectin, PAI-1 (Weisberg
et al., 2003; Xu et al., 2003). PAI-1 is considered to be an
anti-fibrinolytic adipokine synthesized by macrophages in
adipose tissue and the level of PAI-1 in serum is known to
be increased in individuals with obesity (De Taeye et al.,
2005). Increased PAI-1 expression that accompanies abdom-
inal obesity is the most well documented abnormality asso-
ciated with the metS. Interestingly, we have found the PAI
gene overexpressed in the monocytes of SZ patients (Drexh-
age et al., 2010b). With regard to dyslipidemia, reduced HDL
levels are correlated to a high inflammatory set point of
monocytes and macrophages (Sarov-Blat et al., 2007).
The aim of this study was to investigate, using an array-
based system, whether monocyte/macrophage related
‘‘inflammatory’’ cytokines/chemokines/adipokines were
raised in the serum of SZ patients as compared to HC. We
focused in particular on those compounds which have been
described in the literature as abnormal or which we found
previously as abnormally expressed in the monocytes of SZ
and diabetes patients (Padmos et al., 2008a,b; Drexhage
et al., 2010b). We therefore tested for the chemokines
CCL2, CCL4, the cytokines IL-1b, TNF-a, IL-6, PTX3 OPG,
the adipokines leptin, adiponectin and PAI-1 and the adhesion
factor ICAM-1 and studied whether putative elevations in the
serum of SZ patients were related to the disease, to the BMI,
the levels of lipids (HDL, TG), diabetes (hyperglycemia) or
the use of antipsychotic medication.
2. Materials and methods
The study protocols for the inclusion of both the study patients’
samples and HC were reviewed and approved by two indepen-
dent medical ethical review committees METIGG (Utrecht, The
Netherlands) and Utrecht University, respectively.
2.1. Patients with schizophrenia
Chronic stable SZ patients between the ages of 19 and 65
years, with minimum disease duration of 5 years, were
recruited from the mental health care organizations Rijn-
geestgroep (Oegstgeest, Voorhout, and Noordwijkerhout),
De Grote Rivieren (Dordrecht) and Anoiksis, the Dutch orga-
nization for patients with schizophrenia. Most participants of
Schizophrenia is associated with increased serum cytokines, chemokines and adipokines 1903the study were recruited from the semirural part of the Dutch
province Zuid-Holland.
After providing written informed consent, the M.I.N.I. Plus
(Sheehan et al., 1998), a structured diagnostic interview for
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,
4th edition) diagnosis (American Psychiatric Association,
2000), and the available medical records were used for a
DSM-IV diagnosis of schizophrenia or schizoaffective disorder.
The study design as well as the demographic data of the study
population has been described before (Cohen et al., 2006b).
Patients were classified as on typical (n = 39/144) and atypical
(n = 94/144) medication. The two treatment groups did not
differ in age, BMI, or waist-to-hip ratio.
Although the group of SZ patients share a long history of
antipsychotic medication use, a small subgroup (n = 11) was
currently drug-free. This subgroup did not use anti-psychotic
medication for at least 3 months. The drug-free population
had significantly lower BMI and higher HDL (Table S3)
The demographic data for the SZ patients are listed in
Table 1.
2.2. Healthy controls
HC (n = 138) were laboratory staff, medical staff and medical
students at the Erasmus MC. The inclusion criteria for HC were
an absence of any major psychiatric disorder including schizo-
phrenia, bipolar and major depressive disorder and an absent
history of these disorders in first-degree family members. The
HC had to be in good health and free of any diagnosed medical
disorder or illness for at least 2 weeks before blood with-
drawal. The demographic data for the HC are listed in Table 1.
2.3. Clinical variables
Clinical variables including TG, HDL, mean fasting glucose
levels were only determined in the SZ patient group. BMI wasTable 1 Patient characteristics. Characteristics of HC, SZ patien
HC SZ 
Group size n 138 98 
Age (mean) 18—62 (33) 19—65 (40) 
Gender
Female n (%) 84 (61%) 24 (24%) 
Male n (%) 54 (39%) 74 (76%) 
Medication use
None 138 8 
Typical  26 
Atypical  64 
Clozapine  14 
Risperidone  22 
Olanzapine  25 
Quetiapine  3 
BMI mean (range) 24(18—36)a 26 (18—35) 
TG mean (range) mmol/l NA 1.4 (0.3—9.0) 
HDL mean (range) mmol/l NA 1.1 (0—5.6)a
Diabetes mellitus (%) 0 5 (5%) 
Values in bold denote a significant difference between two groups.
a BMI was measured in 42 HC.determined only in 43 of 144 HC. Overall, the HC were
considered lean.
The metabolic syndrome (metS) was defined according to
a modified definition of the NCEP-ATP III (National Choles-
terol Education Program (U.S.). Expert Panel on Detection
Evaluation and Treatment of High Blood Cholesterol in Adults,
2002).
Hyperglycemia was diagnosed when the mean fasting
glucose plasma level was between 6.1 and 7.0 mmol/l, or
when the oral glucose tolerance test (OGTT) plasma glucose
levels at T = 120 min were between 7.8 and <11.1 mmol/l.
The glucose measurements were performed in the morning
between 09:00 h and 11:00 h. In addition, we also deter-
mined the metS according to International Diabetes Federa-
tion guidelines (Alberti et al., 2005), but this did not result in
a change of the total number of SZ patients with metS.
2.4. Laboratory methods
2.4.1. Serum collection
After a 12 h fasting period a blood sample was taken between
09:00 h and 11:00 h in both populations. Blood was collected
in clotting tubes for serum preparation and stored at 20 8C.
2.4.2. Cytokine and adipokine measurements
The serum cytokine/chemokine/adipokine concentrations
were measured using the Cytometric Bead Array kits (BD
Biosciences, San Diego, USA) according to the manufacturer’s
protocol. Samples were analyzed with a Calibur flow cyt-
ometer (BD Biosciences, San Diego, USA) using BD FCAP Array
Software (BD Biosciences). Results are expressed as pico-
grams per milliliter.
Undetectable cytokine levels were considered as 0 pg/ml
and included in the statistical analysis. Subjects with missing
serum cytokine values as a result of limited amount of serum
were excluded from the specific test.ts and SZ patients with the metS.
p-Value SZ-metS p-Value p-Value
HC vs. SZ SZ vs.
SZ-metS
HC vs.
SZ-metS
46
<0.001 22—65 (41) 0.857 <0.001
19 (41%)
27 (49%)
3
13
30
11
9
10
0
<0.001 32 (19—47) <0.001 <0.001
NA 2.8 (0.6—9.4) <0.001 NA
NA 0.9 (0.0—1.8) <0.001 NA
. 7 (15%) . .
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Statistical analysis was performed using the SPSS 20 (IBM, Inc.)
package for Windows. Data were tested for normal distribution
using the Kolmogorov—Smirnov test. Depending on the distri-
bution pattern and the total number of subjects, parametric
(normal distribution) or nonparametric group comparison
(Mann—Whitney U and Kruskal—Wallis H-tests) were applied.
Correlations were determined by Spearman correlation. The
effect of components of the metS on the serum cytokine/
chemokine/adipokine concentrations were determined by
generalized linear models withbootstrapping to improvemodel
fit. Levels of significance were set at p = 0.05 (two-tailed). The
specific tests and group size are mentioned in tables, footnotes
and in figure legends. Graphs were designed with Graphpad
Prism 5.04 (Graphpad Software, Inc) for windows.
3. Results
We compared the serum cytokines/chemokines/adipokines
concentrations between the study groups, i.e. HC, SZ
patients with and without the metS. The studied serum
proteins appeared not normally distributed according to
the Kolmogorov—Smirnov test; therefore we used non-para-
metric tests for group comparison and correlation. According
to the Kruskal—Wallis H-test (Table 2) there are significant
differences in serum levels between the study groups for
CCL2, CCL4, IL-1b, TNF-a, IL-6, PTX3, leptin and adiponec-
tin. There was a significant difference in age between the HC
and SZ patient groups (Table 1, p < 0.001). Generalized
linear models applied to our data set demonstrated that
age had a significant, but small effect on adiponectin serum
concentrations in HC and SZ patients (Table S1, b = 3.9).
However, the regression coefficient of age was smaller than
the beta of the disease presence (b = 13.2), indicating that
the effect of age on the adiponectin concentrations was
smaller than the effect of disease. In addition, no significant
correlation between age and the studied clinical variables
was found by Spearman correlation (Table S2).
Similarly, we studied the effect of gender on the serum
protein concentrations with generalized linear models. A
negative beta value corresponding to gender means an
increase in cytokine/chemokine/adipokine concentration
in males, whereas a positive beta corresponds to an increase
of the specific immune compound in females. There was a
significant effect of gender on ICAM-1, TNF-a, leptin and
adiponectin (Table S1). Our finding of higher leptin concen-
tration in the serum of females compared to males is sup-
ported by literature (Rosenbaum et al., 1996; Saad et al.,
1997). For ICAM-1 such literature data is not available. Only
in the case of ICAM-1 and Leptin the effect of gender was
larger than the disease presence and we therefore stratified
ICAM-1 and leptin into male and female groups.
For each of the immune compounds the individual study
groups were thereafter compared using Mann—Whitney
U-tests. Group size, median, interquartile range (IQR) and
p-values are summarized in Table 2.
3.1. CCL2 and CCL4
We found a significant increase of CCL2 (Fig. 1A) and CCL4
(Fig. 1B) in the serum of SZ patients without the metS as
Figure 1 (A) CCL2 and (B) CCL4 serum concentrations. Dots depict individual study subjects, the line represents the median and the
whiskers depict the interquartile range (summarized in Table 2). p-Values were obtained by Mann—Whitney U-tests *p < 0.05,
***p < 0.001.
Schizophrenia is associated with increased serum cytokines, chemokines and adipokines 1905compared to HC ( p < 0.001 for both chemokines), indicating
a significant effect of disease on these chemokines. SZ
patients with the metS had an even more and significantly
raised serum level ( p = 0.017) of CCL2 in comparison to the
serum levels found in patients without the metS. For CCL4
there was also such increase, but this did not reach statistical
significance in comparison to the patients without the metS.
Outcomes of the generalized linear model showed that none
of the components of the metS did have a significant effect on
the CCL2 levels. There was a significant effect of a disturbed
OGTT on the CCL4 serum concentration in the SZ patient
group (Table 3; bOGTT = 28.4, p = 0.035) and we therefore
checked whether there was a correlation between the CCL4
serum concentrations and fasting glucose serum levels
(Spearman correlation). There was no such correlation
(Rs = 0.215, p = 0.017).
3.2. IL-1b, TNF-a, IL-6 and PTX3
We measured significant rises in the serum levels of IL-1b
(Fig. 2A: p < 0.001), TNF-a (Fig. 2B; p < 0.001), IL-6 (Fig. 2C;
p = 0.001) and PTX3 (Fig. 2D; p < 0.001) in SZ patients with-
out the metS in comparison to the HC. The presence of the
metS and its components in SZ patients had no further effect
on the raised serum levels of IL-1b, TNF-a and IL-6.
Decreased HDL had a significant effect on the serum con-
centration of PTX3 (Table 3: bHDL = 78.6, p = 0.05).
3.3. Leptin
Females with SZ (without the metS) had a significantly higher
level of leptin as compared to female HC (Fig. 3A:
p < 0.001). This increase was not present in male patients,
indicating that a disease effect was only noticeable in the
female gender. For both genders the additional presence
of the metS resulted in higher leptin levels, but values only
reached statistical significance for males ( p < 0.001).Gender and BMI appeared to be components of the metS
showing the strongest effect on the serum leptin levels
(Table 3: bgender = 73.4, p = 0.001; bBMI = 31.1, p = 0.003).
3.4. Adiponectin
We found a significant increase in adiponectin levels in the
serum of SZ patients without the metS as compared to HC
(Fig. 3B; p < 0.001), indicating an effect of presence of SZ on
the expression of this adipokine in serum. SZ patients with
the metS had an even more and statistically raised serum
level of adiponectin in comparison to patients without the
metS. Gender, BMI and TG had the strongest effect on
adiponectin serum levels (Table 3: bgender = 9.4,
p = 0.049; bBMI = 8.7, p = 0.001; bTG = 6.3, p = 0.020).
3.5. PAI-1
There was no increase of PAI-1 in the serum of SZ patients
compared to HC irrespective of the absence or presence
of the metS (Fig. 3C). In addition, we did not find any
effect of the components of the metS on serum PAI-1 levels
(Table 3).
3.6. OPG
We did not find differences in OPG serum levels between HC
and SZ patients. However, we did find a significant difference
between HC and SZ patients with the metS (Fig. 4A:
p = 0.017) There was an effect noticeable of a disturbed
OGTT on OPG levels (Table 3: bOGTT = 46.9, p = 0.001).
3.7. ICAM-1
Females with SZ and without the metS had a higher level of
serum ICAM-1 as compared to female HC ( p = 0.026). There
Table 3 Effect of components of the metS on serum cytokines/chemokines/adipokines in SZ patients. Generalized linear model to identify the effect of gender, age and
components of the metS on the serum cytokine/chemokine/adipokine concentrations within the SZ patient group. A negative beta value corresponding to gender means an increase
in cytokine/chemokine/adipokine concentration in males, whereas a positive beta corresponds to an increase of the specific immune compound in females. Similar analysis excluding
the 11 current drug-free patients is shown in Table S5.
Gender Agea BMIa HDLa TGa OGTT
Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI)
CCL2 (n = 143) 3.8 (53.5, 56.4) 13.4 (35.6,9.9) 15.1 (18.2,44.8) 15.2 (70.4,1.2) 18.5 (40.3,7.8) 48.9 (30.8,142.1)
CCL4 (n = 122) 14.9 (30.0, 2.4) 1.6 (10.6,8.9) 2.7 (7.0,12.3) 5.3 (22.1,3.7) 0.5 (8.6,11.9) 28.4 (4.1, 52.4) *
IL-1b (n = 137) 3.3 (7.5,1.5) 0.8 (1.3, 3.0) 2.0 (0.9, 4.8) 0.3 (6.9, 1.1) 1.4 (4.4, 0.2) 0.7 (4.9, 6.7)
TNF-a (n = 129) 23.4 (39.6, 5.5) * 2.3 (6.4, 11.7) 7.9 (3.9, 19.8) 1.5 (19.5, 6.8) 6.9 (19.6, 0.6) 1.7 (26.2, 21.1)
IL-6 (n = 126) 15.7 (48.9, 11.4) 2.9 (6.5, 12.8) 13.2 (2.1, 35.1) 0.3 (17.0, 9.3) 7.3 (26.1, 3.3) 12.7 (43.5, 11.0)
PTX3 (n = 142) 73.3 (104.8, 292.0) 8.1 (79.8, 75.8) 9.8 (112.9, 95.3) 78.4 (266.1, 38.8) * 17.9 (103.6, 45.0) 38.9 (240.4, 146.6)
Leptin (n = 122) 74.3 (47.1, 103.2) ** 7.1 (19.1, 3.5) 31.3 (12.5, 47.6) * 0.9 (18.1, 17.2) 8.3 (18.8, 2.1) 35.4 (6.6, 75.4)
Adiponectin (n = 122) 9.4 (18.4, 0.5) * 1.9 (5.7, 2.6) 8.7 (2.9, 13.4) ** 1.9 (15.3, 0.4) 6.3 (0.9, 12.8) * 7.8 (19.6, 3.4)
PAI-1 (n = 122) 0.5 (1.3, 0.4) 0.0 (0.4, 0.4) 0.4 (0.1, 0.8) 0.1 (0.7, 0.3) 0.2 (0.1, 0.5) 0.3 (1.3, 0.7)
OPG (n = 122) 13.6 (8.6, 36) 0.1 (10.5, 10.5) 7.7 (6.7, 21.9) 1.2 (25.4, 8.9) 2.8 (8.4, 13.3) 46.9 (21.6, 76.3) **
ICAM-1 (n = 122) 234.7 (434.4, 13.6) * 41.4 (150.3, 68.6) 65.7 (195.0, 59.9) 74.4 (355.0, 20.2) 25.7 (143.5, 41.6) 221.5 (530.9, 101.7)
Values in bold denote a significant effect.
p-Values are depicted as:
* p < 0.05.
** p < 0.01.
a Age, BMI, HDL and TG were standardized as z-scores to correct for the effect size of each cofactor.
Figure 2 (A) IL-1b, (B) TNF-a, (C) IL-6 and (D) PTX3 serum concentrations. Dots depict individual study subjects, the line represents the median and the whiskers depict the
interquartile range (summarized in Table 2). p-Values were obtained by Mann—Whitney U-tests **p < 0.01, ***p < 0.001.
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Figure 3 (A) Leptin, (B) adiponectin and (C) PAI-1 serum concentrations. Dots depict individual study subjects, the line represents
the median and the whiskers depict the interquartile range (summarized in Table 2). p-Values were obtained by Mann—Whitney U-tests
***p < 0.001.
Figure 4 (A) OPG, (B) ICAM-1 serum concentrations. Dots depict individual study subjects, the line represents the median and the
whiskers depict the interquartile range (summarized in Table 2). p-Values were obtained by Mann—Whitney U-tests *p < 0.05.
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indicating that a small disease effect was only noticeable
in the female gender (Fig. 4B). For both genders the addi-
tional presence of the metS and its components (Table 3) did
not have any effect on ICAM-1 levels.
3.8. Effect of antipsychotic medication
We studied the effect of antipsychotic medication use (users
vs. currently 11 non-users) as well as the type of antipsycho-
tic medication (as summarized in Table 1) on the serum
cytokine/chemokine/adipokine levels and did not find a
correlation with the measured levels (Table S3). The useof antipsychotic medication did correlate weakly, but sig-
nificantly with HDL (Rs = 0.174, p = 0.03) and the BMI
(Rs = 0.209, p = 0.012).
Omission of the 11 drug-free cases (Table S4) from the
statistical analysis did not change the outcome of the study
group comparison shown in Table 3. Furthermore, general-
ized linear models to study the effect of the components of
the metS on the serum cytokine/chemokine/adipokine levels
did not reveal any major changes when removing the 11 drug-
free patients from the analysis (Table S5). However, the
effect of HDL levels on PTX3 serum levels, the effect of
TG on serum adiponectin levels and the effect of a positive
outcome of the OGTT on CCL4 lost significance.
Table 4 Results synopsis. Synopsis of results obtained from the statistical models.
Disease Age Gender metS BMI TG HDL OGTT
Chemokines
CCL2 + + +   +    
CCL4 + + +       + +
Pro-inflammatory cytokines
IL-1b + + +       
TNF-a + + +  + (<)     
IL-6 + +       
PTX3 + + +      + 
Adipokines
Leptin + + + (,)  + + + (,) + + (<) +   
Adiponectin + + +  + (<) + + + + + +  
PAI-1        
OPG (+)b       + +
Adhesion factor
ICAM-1 (+)a (,)  + + + (<)     
+: Represent the effect of each component on the serum cytokine/chemokine/adipokine concentration. ,: effect in females, < effect in
males.
a Not significant after Bonferroni correction.
b Significant difference in OPG serum concentration between HC and SZ patients suffering from the metS.
1908 W. Beumer et al.Since the use of antipsychotic medication resulted in a
higher BMI (Table S3, p = 0.012) and a reduced HDL (Table S3,
p = 0.039) in our series, the omission of the drug-free patients
(and thus of the leanest patients with the most favorable lipid
spectrum) might have influenced indirectly the loss of cor-
relation between the lipid levels/OGTTon PTX3, adiponectin
and CCL4 levels.
Since it has been found that clozapine treatment
increases serum IL-6 concentrations (Maes et al., 1997)
and since clozapine mobilized CD34 progenitor cells (Loffler
et al., 2010), we tested for clozapine correlation separately
in our group of SZ patients. A considerable proportion of SZ
patients in this study were taking clozapine (n = 25). Spear-
man correlation indicated that the use of clozapine did not
correlate with any of the serum cytokine/chemokine/adipo-
kine levels (Table S6). In addition no differences in serum
cytokine/chemokine/adipokine levels between clozapine
users and users of other anti-psychotic medication were
detected (Table S7).
4. Discussion
Although many studies report increased serum levels of
monocyte/macrophage related cytokines IL-1b, IL-6, TNF-
a in SZ patients (Drexhage et al., 2010b), the majority of
studies did not take confounders such as age, gender, BMI,
medication and presence of the metS into account.
This study shows an elevation of the monocyte/macro-
phage cytokines IL-1b, TNF-a, IL-6, PTX3, the chemokines
CCL2 and CCL4 and the adipokines leptin and adiponectin in
the serum of patients with chronic schizophrenia (for synop-
sis of findings see Table 4). Multivariate analysis showed that
these elevations were linked to both the disease state itself
as well as to confounders such as gender (ICAM-1, leptin, TNF-
a and adiponectin), a high BMI (leptin, adiponectin), hyper-
glycemia (CCL4 and to some extent OPG), reduced levels of
HDL/high levels of TG (adiponectin and PTX3) and/or thepresence of metS in general (CCL2, leptin and adiponectin).
IL-1b and IL-6 were the only cytokines raised in the serum of
SZ patients not affected by any of the here studied con-
founding factors.
PAI-1 was not raised in the serum of chronic schizophrenia
patients. Carrizo et al. (2008) did not find significant differ-
ences in serum PAI-1 levels between SZ patients and their
healthy relatives; however, they did find a strong correlation
of PAI-1 levels and BMI and antipsychotic medication use,
something we did not find.
OPG was slightly elevated in SZ patients, but only the
difference between HC and SZ-metS was significant and a
prime role for hyperglycemia in this subgroup of patients is
likely (Tables 3 and 4). Hope et al. (2010) did find increased
OPG levels in SZ patients, but these authors did not take the
presence of the metS into account.
Monocyte migration into the tissues is — besides on the
action of chemokines — also dependent on the action of
integrins and the ICAM-1 system is important in this. The
concentration of the adhesion molecule ICAM-1 was elevated
in SZ patients, but with only a p-value of 0.026 and linked to
gender. It is questionable whether we should apply Bonferroni
testing on this limited array of cytokines/chemokines/adipo-
kines/adhesion factors studied here (in particular since we
focused on monocyte/macrophage compounds from a hypoth-
esis-driven approach), but in doing so the significance for ICAM-
1 levels was lost (see legend Table 2, not for the other studied
compounds). Despite the questionable significance for the rise
in ICAM-1, it is in line with results from a previous study
(Schwarz et al., 2000), where also increased ICAM-1 levels
were detected in SZ patients. However elevations in ICAM-1
were found in that study in medicated patients, while drug-
naı¨ve patients did not show such increase. Therefore the
authors suggested that the anti-psychotic medication was
responsible for the rise in serum ICAM-1 levels. Only a small
group of our SZ patients (n = 11/144) did not use antipsychotic
medication at the time of serum collection, but they had used
such medication in the past.
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the immune compounds in this study between medicated vs.
currently non-medicated chronic SZ patients (including clo-
zapine), it is possible that long term medication in the
presently 11 drug-free patients may have had a long lasting
stimulating influence on the immune system being respon-
sible for a long-lasting rise in the level of the immune
compounds. It must be noted however that antipsychotic
medication, has in general an immune suppressive effect
(Janssen et al., 2010), confirmed by a meta-analysis of (Miller
et al., 2011), who found significantly decreased IL-1b and IL-6
levels after initiation of antipsychotic treatment. Suffice to
say that more in depth studies on the effects of anti-psycho-
tic medication on the levels of the here reported cytokines/
chemokines/adhesion molecules is indicated.
Our study has several limitations. First, the drug-free
group of patients is of insufficient size and insufficient length
of — drug-free — time. Secondly, the HC group composed of
laboratory and hospital staff was not only younger than the
SZ patients and had a lower BMI than the SZ patients, but
maybe even more important, they had a higher socioeco-
nomic status (SES) than the SZ patients. Because of the
normal BMI, we assume that these healthy hospital and
medical faculty staff were not or hardly suffering from
the metS, though exact data are not available on the
HDL, TG and OGTT values in the healthy control group. In
comparison to the levels found in this HC group, the levels
CCL4, IL-1b, TNF-a, IL-6, PTX3, leptin (females) and adipo-
nectin were significantly raised in the serum of SZ patients
without the metS. If the prevalence of the metS in our
healthy controls would have been considerable and would
have had an impact, it would have blurred the difference
between the two groups (since the metS has an increasing
effect on the cytokine/chemokine/adipokine levels). We
are therefore confident that our data strongly suggest that
the higher expression of CCL4, IL-1b, TNF-a, IL-6, PTX3,
leptin and adiponectin are linked to the disease state of SZ
itself and not to the presence of the metS.
A low SES was found to be correlated to higher levels of
circulating inflammatory markers including IL-6 and TNF-a
(O’Connor et al., 2009). However, strong association of
smoking, drinking, less exercise and obesity with low SES
might explain this increase in inflammatory makers. Schizo-
phrenia is associated with a greater probability of ever daily
smoking compared to other mood disorders and the general
population (de Leon et al., 2002). Tobacco smoking leads to
increased IL-6 levels in the serum; decreased TNF-a however,
was found to be associated with smoking in females only
(Haddy et al., 2005).
Suffice to say, that our data should be verified in new
cohorts with healthy controls matched for age, gender, signs
and symptoms of the metabolic syndrome, smoking habits
and particularly socioeconomic status.
In a previous study of serum cytokine levels, using the
same assay, but in younger (mean age 24) psychotic recent-
onset SZ patients with a treatment duration under 3
months, the levels of CCL2, IL-1b, TNF-a, IL-6 and PTX3
were found to be normal (Drexhage et al., 2011). However,
we did find in this young group of SZ patients an up
regulation in the circulating monocytes for CCL2, IL-1b,
TNF-a, IL-6 and PTX3 mRNA and we then argued that
there must be a control over the excessively up regulatedmonocyte genes not to result in excessive protein produc-
tion. The present data suggest that during the development
of the disease to the chronic phase, these control factors
are lost. However our data did not clearly indicate which
conditions were responsible for breaking control, since the
presence of the metS did not influence the expression of the
studied cytokines apart from that of CCL2, leptin (in males)
and adiponectin. It might be that the cumulative treatment
with antipsychotic medication resulting in obesity (this
report confirmed the correlation of antipsychotic medica-
tion with the BMI) has an indirect increasing effect on serum
cytokine levels; macrophages in fat are producers of (pro-
inflammatory) cytokines including ICAM-1, CCL2, CCL4,
IL-1b, TNF-a, IL-6 and adipokines leptin, adiponectin and
PAI-1 (Weisberg et al., 2003; Xu et al., 2003). However, we
were unable to find an effect of increased BMI on the serum
levels of the mentioned cytokines (Table 3). Also in a
separately small series study of morbid obese non-SZ
patients, we could not find higher serum levels of the above
mentioned inflammatory cytokines in comparison to lean
controls (van der Weerd et al., 2012).
The diabetes found in antipsychotic treated SZ patients
has three outstanding characteristics. First it occurs at a
younger age (Cohen et al., 2006a; De Hert et al., 2006).
Second, it might develop into a diabetic form of ketoacidosis
(DKA) or a hyperglycemic hyperosmolar state (HHS) (Koller
et al., 2001, 2003, 2004; Koller and Doraiswamy, 2002).
Third, the increased incidence of DKA/HHS notwithstanding,
no indications of autoimmune origin were found: antibodies
and antibodies to GAD65 are not present in SZ patients with
diabetes (Cohen et al., 2005). Although we did not find a
direct correlation between CCL4 serum levels and fasting
glucose or glucose levels after the OGTT, we did find a small,
but significant effect of CCL4 levels on the outcome of the
OGTT, indicating that the increase of CCL4 is linked to the
presence of impaired glucose tolerance or (pre)-diabetes in
SZ patients. In addition, CCL4 was encountered as a pre-
dominant T2D-expressed monocyte gene of T2D patients in a
preliminary set of gene-finding experiments in monocytes of
T2D patients (unpublished data). Collectively these data
support a view that CCL4 is an important gene in both SZ
and T2D.
In conclusion, chronic schizophrenia patients clearly
show an activated monocyte/macrophage system as evi-
denced by raised serum levels of the chemokines CCL2
and CCL4, the cytokines IL-1b, TNF-a, IL-6 and PTX3, the
adipokines leptin and adiponectin. Although many of these
immune compounds were found linked to gender, the metS
and hyperglycemia/diabetes, the most dominant linkage
was found with the disease state of schizophrenia itself
supporting our earlier expressed view (studying psychotic
patients with recent onset schizophrenia) that immune
system activation is a key to understand the pathogenesis
of schizophrenia (Drexhage et al., 2011). These findings
support the rational for an (add-on) anti-inflammatory
treatment in patients with chronic SZ.
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